Conversion of Performance Shares
Released
Released
Announcement PDF
Conversion of Performance Shares
Sydney Australia, 26 June 2020: Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the
Company developing a New Class of Broad-Spectrum Synthetic antibiotics, wishes to advise
that the milestone associated with 7,398,174 of the Company’s Class C unquoted Performance
Shares (Eligible Shares) has been achieved.
On 20 August 2015, the Company issued 8,754,423 Class C Performance Shares (which
include the Eligible Shares) to directors and key management personnel of the Company on
terms which included that:
a) if the volume weighted average price of shares as traded on ASX over 20 consecutive
trading days on which the shares are traded is not less than $0.60 within 5 years from
the date of issue (Milestone);
b) then each Eligible Share will convert into one fully paid ordinary share on achievement
of the Milestone.
The Company will issue and seek quotation for 7,398,174 fully paid ordinary shares as a result
of the conversion of the Eligible Shares in due course. These shares will be issued to current
directors of the Company.
The Company has determined that the remaining 1,356,249 Class C Performance Shares, held
by former directors and key management personnel of the Company are ineligible for
conversion, and as a result will not be converted into fully paid ordinary shares of the Company.
This announcement has been approved for release by Recce Pharmaceuticals Board
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation
of a New Class of Synthetic Antibiotics with Broad Spectrum activity designed to address the
urgent global health problem of antibiotic resistant superbugs.
Recce antibiotics are unique – their potency does not diminish even with repeated use, which is a common
failure associated with existing antibiotic use and the resulting emergence of resistant superbugs.
Patented lead candidate RECCE® 327, wholly owned and manufactured in Australia, has been
developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus
bacteria – including their superbug forms.
The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under
the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation,
plus 10 years of market exclusivity post approval.
Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials.
Recce’s anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies
targeting synergistic, unmet medical needs.
Share your feedback
Discover